🇺🇸 FDA
Pipeline program

CLBS16

CLBS16-P02

Phase 2 mab terminated

Quick answer

CLBS16 for Coronary Microvascular Dysfunction is a Phase 2 program (mab) at LISATA THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
LISATA THERAPEUTICS, INC.
Indication
Coronary Microvascular Dysfunction
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials